Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Glioblastoma (GBM) represents an aggressive brain malignancy with limited treatments. Shanley et al. engineer NK cells to express interleukin (IL)-21, which show superior safety and long-term anti-tumor activity compared to IL-15 NK cells. Key transcription factors like CEBPD drive this enhanced function, suggesting that IL-21 reprograms NK cells epigenetically, enhancing their therapeutic efficacy against GBM.